We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.84%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$546M
AUM Growth
-$31.1M
Cap. Flow
+$46.9M
Cap. Flow %
8.6%
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$20.3M
2
HCA icon
HCA Healthcare
HCA
+$15.4M
3
COO icon
Cooper Companies
COO
+$9.29M
4
CRL icon
Charles River Laboratories
CRL
+$9.07M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.02M

Top Sells

Rank Stock Value
1
DHR icon
Danaher
DHR
+$14.6M
2
LNTH icon
Lantheus
LNTH
+$14.3M
3
WAT icon
Waters Corp
WAT
+$10.8M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.89M
5
SDGR icon
Schrodinger
SDGR
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUGX
76
DELISTED
Augmedix, Inc. Common Stock
AUGX
$1.94M 0.35%
+376,082
New +$1.76M
SLN
77
Silence Therapeutics
SLN
$641M
$1.89M 0.35%
192,879
+7,801
+4% +$57.6K
COGT icon
78
Cogent Biosciences
COGT
$6.76B
$1.89M 0.35%
193,637
+7,855
+4% +$93.2K
PACB icon
79
Pacific Biosciences
PACB
$345M
$1.76M 0.32%
210,580
-114,920
-35% -$1.31M
CDMO
80
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$1.75M 0.32%
185,613
+7,713
+4% +$92.8K
TGTX icon
81
TG Therapeutics
TGTX
$7.58B
$1.75M 0.32%
209,319
-11,315
-5% -$158K
AMAM
82
DELISTED
Ambrx Biopharma Inc
AMAM
$1.73M 0.32%
+150,000
New +$2.04M
MORF
83
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.72M 0.31%
+75,000
New +$3.94M
TNGX icon
84
Tango Therapeutics
TNGX
$4.31B
$1.53M 0.28%
+135,920
New +$829K
GPCR icon
85
Structure Therapeutics
GPCR
$3.83B
$1.51M 0.28%
+30,000
New +$967K
BDTX icon
86
Black Diamond Therapeutics
BDTX
$121M
$1.49M 0.27%
520,587
+20,587
+4% +$75.8K
LAB icon
87
Standard BioTools
LAB
$312M
$1.45M 0.27%
+500,000
New +$1.31M
TELA icon
88
TELA Bio
TELA
$32.3M
$1.33M 0.24%
166,725
+7,699
+5% +$71.5K
LXRX icon
89
Lexicon Pharmaceuticals
LXRX
$1.05B
$1.24M 0.23%
1,136,413
-194,203
-15% -$341K
ACRS icon
90
Aclaris Therapeutics
ACRS
$860M
$971K 0.18%
141,758
-51,839
-27% -$443K
IRWD icon
91
Ironwood Pharmaceuticals
IRWD
$714M
$963K 0.18%
+100,000
New +$980K
XFOR icon
92
X4 Pharmaceuticals
XFOR
$425M
$872K 0.16%
26,667
-98,886
-79% -$4.31M
IMUX icon
93
Immunic
IMUX
$217M
$827K 0.15%
56,251
+2,276
+4% +$43.8K
LQDA icon
94
Liquidia Corp
LQDA
$7.01B
$743K 0.14%
117,253
-163,881
-58% -$1.18M
INZY
95
DELISTED
Inozyme Pharma
INZY
$739K 0.14%
175,896
+7,106
+4% +$36.1K
ASLN
96
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$701K 0.13%
46,593
-16,735
-26% -$307K
ETON icon
97
Eton Pharmaceutcials
ETON
$1.14B
$688K 0.13%
+165,000
New +$637K
TKNO icon
98
Alpha Teknova
TKNO
$397M
$652K 0.12%
233,746
+57,432
+33% +$151K
CUTR
99
DELISTED
Cutera, Inc.
CUTR
$602K 0.11%
+100,000
New +$1.27M
AFIB
100
DELISTED
Acutus Medical Inc
AFIB
$553K 0.1%
794,145
+32,120
+4% +$20.8K
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Parkman Healthcare Partners held 117 positions worth $546M, down 5.4% from $577M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners deployed $46.9M of net new capital in Q3 2023, opening 22 new positions and adding to 53 existing holdings. Its largest new stake was HCA Healthcare: 56,160 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Lantheus, an estimated $14.3M trimmed.

  • Parkman Healthcare Partners's largest Q3 2023 buy was HCA Healthcare: 56,160 shares worth $13.8M.
  • Parkman Healthcare Partners added most to DexCom in Q3 2023, an estimated $20.3M increase.
  • Parkman Healthcare Partners's biggest Q3 2023 reduction was Lantheus, cutting an estimated $14.3M.
  • Parkman Healthcare Partners fully exited Danaher in Q3 2023, selling an estimated $14.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $546M portfolio in Q3 2023.
  • Parkman Healthcare Partners opened 22 new positions and closed 15 in Q3 2023.
  • Parkman Healthcare Partners's portfolio value fell 5.4% quarter-over-quarter to $546M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.